MX2009007405A - Compuestos con una combinacion de antagonismo de cb1 cannabinoide e inhibicion de recaptacion de serotonina. - Google Patents

Compuestos con una combinacion de antagonismo de cb1 cannabinoide e inhibicion de recaptacion de serotonina.

Info

Publication number
MX2009007405A
MX2009007405A MX2009007405A MX2009007405A MX2009007405A MX 2009007405 A MX2009007405 A MX 2009007405A MX 2009007405 A MX2009007405 A MX 2009007405A MX 2009007405 A MX2009007405 A MX 2009007405A MX 2009007405 A MX2009007405 A MX 2009007405A
Authority
MX
Mexico
Prior art keywords
compounds
cannabinoid
combination
methods
serotonin reuptake
Prior art date
Application number
MX2009007405A
Other languages
English (en)
Inventor
Cornelis G Kruse
Josephus H M Lange
Original Assignee
Solvay Pharm Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Bv filed Critical Solvay Pharm Bv
Priority claimed from PCT/EP2008/050181 external-priority patent/WO2008084057A1/en
Publication of MX2009007405A publication Critical patent/MX2009007405A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Esta invencion se refiere a compuestos con una combinación de antagonismo de CB1 cannabinoide e inhibición de la recaptación de serotonina, a composiciones farmacéuticas que contienen estos compuestos, a métodos para preparar los compuestos, métodos para preparar intermediarios útiles para su síntesis, y métodos para preparar composiciones; la invención también se refiere al uso de tales compuestos y composiciones, particularmente su uso en administrarlos a pacientes para lograr un efecto terapéutico en psicosis, ansiedad, depresión, deficiencias de atención, trastorno cognitivos, obesidad, dependencia de los fármacos, enfermedad de Parkinson, enfermedad de Alzheimer, trastornos del dolor, trastornos de dolor neuropático y trastornos sexuales; en particular la invención se refiere a compuestos de la fórmula general (1): (ver fórmula (1)) en donde los símbolos tienen los significados dados en la especificación.
MX2009007405A 2007-01-10 2008-01-09 Compuestos con una combinacion de antagonismo de cb1 cannabinoide e inhibicion de recaptacion de serotonina. MX2009007405A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07100323 2007-01-10
PCT/EP2008/050181 WO2008084057A1 (en) 2007-01-10 2008-01-09 Compounds with a combination of cannabinoid-cb1 antagonism and serotonin reuptake inhibition

Publications (1)

Publication Number Publication Date
MX2009007405A true MX2009007405A (es) 2009-07-17

Family

ID=38069361

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009007405A MX2009007405A (es) 2007-01-10 2008-01-09 Compuestos con una combinacion de antagonismo de cb1 cannabinoide e inhibicion de recaptacion de serotonina.

Country Status (6)

Country Link
CN (1) CN101809000A (es)
AR (1) AR064765A1 (es)
BR (1) BRPI0806452A2 (es)
MX (1) MX2009007405A (es)
SA (1) SA08280759B1 (es)
TW (1) TW200845963A (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103547263B (zh) * 2010-11-18 2015-12-09 詹里恩探索公司 对于治疗代谢性疾病，包括肥胖症和糖尿病有用的大麻素受体拮抗剂/反相激动剂
CN104666291A (zh) * 2013-11-26 2015-06-03 山东绿叶制药有限公司 去甲基文拉法辛苯甲酸酯类化合物在制备改善性功能障碍药物中的应用
CN114848641A (zh) * 2016-05-25 2022-08-05 田边三菱制药株式会社 用于治疗焦虑症的化合物或其代谢物
KR102036909B1 (ko) * 2017-11-28 2019-10-25 한국과학기술원 신규 디스토니아 치료용 약학적 조성물
KR20210061357A (ko) 2018-09-04 2021-05-27 미네르바 뉴로사이언스즈, 인크. 통증을 치료하기 위해 페녹시프로필아민 화합물을 사용하는 방법
BR112022015570A2 (pt) * 2020-02-06 2022-11-22 London Pharmaceuticals And Res Corporation Ésteres sulfato de canabinoide, seus sais e usos destes

Also Published As

Publication number Publication date
CN101809000A (zh) 2010-08-18
TW200845963A (en) 2008-12-01
SA08280759B1 (ar) 2011-05-04
AR064765A1 (es) 2009-04-22
BRPI0806452A2 (pt) 2011-09-06

Similar Documents

Publication Publication Date Title
HK1154587A1 (en) Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
TN2012000231A1 (en) Quinoline amide m1 receptor positive allosteric modulators
MX2011007774A (es) Derivados de isoxazol-isoxazol e isoxazol-isotiazol.
MX2009007405A (es) Compuestos con una combinacion de antagonismo de cb1 cannabinoide e inhibicion de recaptacion de serotonina.
MX2012002583A (es) Moduladores de piranil aril metil benzoquinazolinona alostericos positivos del receptor m1.
MX2011011489A (es) Derivados de isoxazol-piridina.
MY179527A (en) Catecholamine derivatives useful for the treatment of parkinson's disease
EP2582676A4 (en) POSITIVE ALLOSTERIC TETRAHYDROCHINOLINE AMID M1 RECEPTOR MODULATORS
EP2037739A4 (en) POSITIVE ALLOSTERIC EFFECTORS OF BENZYL-SUBSTITUTED QUINOLONE M1 RECEPTOR
MY146662A (en) Novel n-(8-heteroaryltetrahydronaphtalene-2yl) or n-(5-heteroarylchromane-3-yl) carboxamide derivatives for the treatment of pain
EA200970310A1 (ru) Сульфонилпиразольные и сульфонилпиразолиновые производные карбоксамидина как антагонисты 5-ht
MX344142B (es) (8-aza-biciclico[3.2.1]oct-8-il)-[5-(1h-pirazol-4-il)-tiofen-3-il ]-metanonas 3, 3-disubstituidas como inhibidores de 1(beta)-hsd1.
MX2011011273A (es) Derivados de isoxazol-pirazol.
IN2012DN02590A (es)
PH12013502376A1 (en) Arylsulfonyl pyrazoline carboxamidine derivatives as 5-ht6 antagonists
MX2011011477A (es) Derivados de isoxazol-piridazina.
GB2454615A (en) Antidiabetic azabicyclo (3.1.0) hexan compounds
CL2011000137A1 (es) Uso de compuestos derivados de 4,5-dihidro-oxazol-2-ilamina para tratar trastornos de ansiedad, trastornos bipolar, esquizofrenia, enfermedades neurológicas, epilepsias, migraña, trastornos metabólicos, trastornos cardiovasculares, entre otros; compuestos derivados de 4,5-dihidroxazol-2-ilamino; proceso de síntesis
PH12015500860A1 (en) 2-phenyl -5- heterocyclyl -tetrahydro-2h- pyran-3-amine compounds for use in the treatment of diabetes and its associated disorders
MX2011011490A (es) Derivados de isoxazol-tiazol como agonistas inversos del receptor de acido gamma-aminobutirico a (gaba a), para usarse en el tratamiento de trastornos cognitivos.
IL198926A0 (en) Compounds with a combination of cannabinoid-cb1 antagonism and acetylcholinesterase inhibition
ATE552257T1 (de) Positive allosterische chinolizidinon-m1- rezeptormodulatoren
EA200970672A1 (ru) Соединения с комбинацией каннабиноид-свантагонизма и ингибирования обратного захвата серотонина
MX2016001080A (es) Derivados de pirroloquinolina como antagonistas de 5-ht6, metodo de preparacion y uso de los mismos.
WO2009117283A3 (en) Quinolizidinone m1 receptor positive allosteric modulators